PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Heparinoids”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1977

[Effect of heparinoids on the blood sugar level and blood lipids in diabetes mellitus].

The paper is a clinical experimental work, studying the heparinoid effect upon blood sugar level, blood lipid fractions, endogenic heparin and lipo-brigther-becoming activity in diabetics. Heparinoids are applied in acute experiment. A total of 37 subjects were examined--22 diabetics with adult type of diabetes, 10 clinically healthy subjects and 5 diabetics examined only with 500 ml physiologic salt solution. The same patients were examined with heparin as well for a comparison. Blood sugar, NEFA, lipolyzing activity, total lipids, total cholesterol, beta-lipoproteins, total phospholipids, triglycerides and endogenic heparin were determined prior to and post infusion introduction of heparinoids. The results reveal that heparinoids have two basic biochemical effects decrease blood sugar lever in diabetics and change the blood lipid fraction level. They depend on the structural peculiarities of the preparations. Heparinoids stimulate heparin activity as well, through which they realize their biochemical effect to a certain extent. The decreasing effect on blood sugar level of heparinoids is stronger as compared with heparin.

Adolescent↗
PubMed1992

Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.

Progressive thrombocytopenia may develop in as many as 5% of patients receiving heparin anticoagulation. In these patients, the risk of thromboembolic complications as well as continued thrombocytopenia necessitates discontinuation of heparin and initiation of an alternative anticoagulant when indicated. The heparinoid Lomoparan (Org 10172) is a mixture of several non-heparin low molecular weight glycosaminoglycans with proven anticoagulant efficacy that is generally non-reactive with platelets in the presence of plasma from patients with heparin induced thrombocytopenia, whereas standard heparin will induce platelet aggregation. We evaluated the role of heparinoid as a potential alternative anticoagulant in patients with heparin induced thrombocytopenia. During a 6 month period, we identified six patients with heparin induced thrombocytopenia who required an alternative parenteral anticoagulant, four as primary treatment for specific medical problem, and two as anticoagulation during a necessary surgical procedure. Heparinoid was used successfully in both medical and surgical patients requiring parenteral anticoagulation. In no case was there an exacerbation of the thrombocytopenia nor thromboembolic complications while on heparinoid therapy. Three of our patients sustained hemorrhagic complications, predominantly in the post-surgical setting in association with elevated anti-factor Xa levels and additional anticoagulant agents. We feel that these results confirm the utility of heparinoid anticoagulation in a select subset of patients with heparin induced thrombocytopenia who require continued parenteral anticoagulation.

Anticoagulants↗
PubMed1976

Comparison of a natural heparinoid with sodium and calcium heparin for their effect on the inhibitor of activated factor X.

The reaction between activated factor X (Xa) and its natural inhibitor (XaI) was accelerated in vitro by both sodium heparin and an heparinoid, which was about 3 times less potent than heparin. The s. c. administration in humans of 5,000 units of sodium and calcium heparin was followed by the detection of a plasma activity potentiating XaI. In the majority of subjects, the heparinoid was not effective. These observations indicate that the use of heparinoids should not be considered as an alternative to heparin in the prevention of thromboembolism.

Adult↗
PubMed1992

[Heparin-associated thrombocytopenia: successful therapy of patients after prospective selection of a compatible heparinoid with the heparin-induced platelet activation test].

Diagnosis of HAT type II and treatment of thromboembolic complications in these patients are difficult. Recently we have developed the heparin-induced platelet activation (HIPA) assay which allows a rapid confirmation of the tentative diagnosis of HAT type II. In vitro studies with sera of 25 patients revealed cross-reactivity to the LMW heparins Fragmin, Fraxiparin and Clexane whereas a LMW heparinoid, Org 10172 (Orgaran), did not. In a prospective study this heparinoid was selected for 10 HAT patients, for whom further parenteral anticoagulation was required. In 7 of these patients who received LMW heparins prior to laboratory investigations low platelet counts persisted under treatment with LMW heparins and 2 patients developed additional thromboembolic complications. Upon treatment with Org 10172 platelet counts normalized in 9 patients, in 1 patient thrombocytopenia was unrelated to parenteral anticoagulation, in 1 patient platelet count normalized after discontinuation of Org 10172. We conclude that the HIPA assay allows the laboratory diagnosis of HAT type II and the selection of a compatible heparin or heparinoid for further parenteral anticoagulation.

Cross Reactions↗
PubMed1992

Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.

A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described. He failed to improve when therapy was continued with low-molecular-weight (LMW) heparin (Fragmin, Kabi Pfrimmer, Erlangen, FRG). By means of the in vitro heparin-induced platelet activation (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum. In contrast, the LMW heparinoid Org 10172 (Organon, Oss, The Netherlands) did not cause platelet activation. When the patient was subsequently treated by parenteral administration of Org 10172 as anticoagulant over a period of several weeks the number of platelets rapidly increased and the patient almost completely recovered. This case shows that strong in vivo and in vitro cross-reactivity between standard heparin and LMW heparins may occur, but can be avoided by the use of a novel heparinoid, Org 10172. The HIPA assay provides a simple and sensitive laboratory method for the choice of an innocuous heparin or heparinoid for continued parenteral anticoagulation.

Aged↗
PubMed1992

Synthesis and non-thrombogenicity of heparinoid polyurethaneureas.

Unsaturated polyurethaneureas were synthesized from 4,4'-diphenylmethane diisocyanate, 1,2-diaminopropane and polybutadiene containing hydroxyl groups at both ends of a chain. The polyurethaneureas were cast as a film and subsequently treated with N-chlorosulphonyl isocyanate to produce sulphamate and carboxylate groups on the film surface. The level of in vitro non-thrombogenicity increased with increasing degree of modification. The high blood compatibility is attributed to the low level of platelet stimulation and to heparinoid activity. It was observed that platelet stimulation depends on the surface structure of the original polyurethaneura, and that the heparinoid activity is related with the presence of sulphamate and carboxylate groups.

Animals↗
PubMed1975

Treatment of superficial thrombophlebitis: a randomized, bouble-blind trial of heparinoid cream.

In a prospective, double-blind, randomized trial the efficacy of a heparinoid in ointment form was assessed in treating superficial thrombophlebitis developing after continuous intravenous infusion. One hundred surgical patients were studied, and clinical examination and the iodine-125-labelled fibrinogen test used to assess the results. The mean time required for the relief of local symptoms and signs and the rate of local decline in radioactivity differed significantly between patients receiving the heparinoid cream and those recieving the placebo.

Administration, Topical↗
PubMed1977

[A clinical constelation in disuse: vitiligo, mastocytosis of the bone marrow, circulating heparinoid, chronic leg ulcer, hypoalbuminemia, ulcerative colitis and hepatic fibrosis].

We report an unusual case. Our patient had vitiligo, ulcerative colitis, hepatic fibrosis, hypoalbuminemia, bone marrow mastocytosis, a circulating heparinoid and chronic leg ulcers. The relationship between some of the components of this constellation seems logical. This is the case with bone marrow mastocytosis and circulating heparinoid. Also, between hypoalbuminemia and colitis and liver disfunction. On the other hand, the relationship between other features does not seem clear in the light of current knowledge.

Adult↗
PubMedDate not supplied

Influence of an oversulphated heparinoid upon hyaluronate metabolism of the human synovial cell in vivo.

Glycosaminoglycans appear to affect proteoglycan metabolism of fibroblasts, human synovial cells, and chondrocytes under in vitro conditions. The influence of an oversulphated heparinoid (Arteparon) on hyaluronate metabolism of the human synovial lining cell was studied by in vivo experiments on human volunteers. A higher production of better polymerized hyaluronic acid was observed after repeated intraarticular injections of this heparinoid into the knees of 2 osteoarthritic patients. After a single injection a statistically significant rise of synovial fluid hyaluronate concentration was observed over 4 days. A higher molecular weight of this molecule was suspected in view of a significant increase of the anomalous viscosity index 2 and 4 days after intraarticular administration.

Arthritis↗
PubMed1978

[Mechanism of action of synthetic heparinoids: results in patients with hypertriglyceridaemia (author's transl)].

The effect of two synthetic heparinoids, SP-54 and Depot-Thrombocid, on serum lipids was studied in 17 patients with primary hyperlipidaemia (types IIb, IV and V of Fredrickson) and 15 healthy persons. SP-54 had no lipid-lowering effect, neither on oral nor rectal suppository application. Intramuscular injection of Depot-Thrombocid, however, resulted in a decrease of serum triglyceride concentrations of maximally 50% after six hours. There was a marked increase in the activity of the two lipolytic enzymes, lipoprotein lipase and hepatic triglyceride lipase in plasma, as well as an increase in free fatty acids and an extension of thrombin time and PTT. Twenty-four hours after injection all values returned to pretreatment levels. Intramuscular administration of Depot-Thrombocid two or three times a week for seven weeks had no lasting effect on serum lipids. However, there were considerable side effects such as haemorrhagic diatheses, hair loss and thrombocytopenia.

Administration, Oral↗
PubMedDate not supplied

Inhibition of adrenal function in man by heparin or heparinoid Ro 1-8307.

Heparin and the heparinoid Ro 1-8307 inhibited the secretory rate of aldosterone in physiological or pathological aldosteronism to the level found in normal subjects on liberal sodium intake. In addition, these compounds inhibited corticosterone biosynthesis, although less markedly than that of aldosterone. Indications of interference with cortisol production have not been found. During drug treatment angiotensin, in doses of 5-10 ng/kg b.wt./min, did not stimulate aldosterone secretion. ACTH responsiveness of the adrenals--indicated by the fractional increases of both aldosterone and corticosterone secretory rates--remained unchanged. In two studies heparin had no consistent effect on plasma renin activity.

11-Hydroxycorticosteroids↗
PubMed1992

Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.

The effects of heparin (5,000 IU i.v.) and the low molecular weight heparinoid Org 10172 (Orgaran) (3,250 anti-Xa units i.v.) on components of the fibrinolytic system were studied in two double-blind, randomised, placebo-controlled, cross-over trials using healthy subjects. In study A (n = 6) the effects were studied during rest and standardized exercise and in study B (n = 6) during a low dose infusion of recombinant tissue-type plasminogen activator (rt-PA; 80 micrograms over 16 min). At rest, heparin and Org 10172 did not influence the plasma concentrations of endogenous t-PA antigen and activity, urokinase-type PA (u-PA) antigen, plasmin activatable pro-urokinase (scu-PA), active urokinase (tcu-PA) and plasminogen activator inhibitor-1 (PAI-1) antigen. Recombinant t-PA antigen and activity during rt-PA infusion were also not affected. During exercise, neither heparin nor Org 10172 influenced the area under the curve (AUC) of t-PA and u-PA antigen and t-PA activity when compared with placebo. Unexpectedly, after heparin the AUC of t-PA activity was 49% larger (range +19 to +245%) than after Org 10172 (p < 0.05). The last difference was considered spurious, scu-PA, tcu-PA and PAI-1 antigen levels at 2 min after termination of exercise were unaffected by both compounds (p > 0.05). Sulphated polysaccharides do not increase fibrinolytic activity of the plasma by changing the concentrations of the components of the fibrinolytic system.

Adult↗
PubMed1975

[Clinical experiences with an external heparinoid in high concentration of effective substance].

396 in-patients and 117 out-patients were treated of study the activity and tolerance of a highly dosed organo-heparinoid in the forms of ointment and gel. Either form was tolerated well; a local allergic cutaneous reaction was seen only in 1 patient. The efficiency of the product, assessed after a classification by points, can be denoted as good for every indication tested.

Clinical Trials as Topic↗
PubMedDate not supplied

[Effect of heparin, heparin derivatives and heparinoids on blood sugar levels of diabetes mellitus patients].

The effect of heparin, its derivatives--sodium iodoheparinate (dioparin), diethylaminoethyltheophylline heparinate (milheparin), and also heparinoids--eleparon, "thrombo" Goltzinger and Sp-51 degrees on the blood sugar level in patients with diabetes mellitus and in healthy persons was studied. The preparations were administered by drop intravenous infusion for 4 hours in a dose corresponding to 10 000 U of heparin activity. Glycemia, lipoproteid lipase, blood lipid fractions, and blood endogenous heparin levels were studied before and after the drug administration. In diabetic patients these preparations decreased the blood sugar level and effected the blood lipid fractions level. Potential mechanisms of the influence on the blood sugar level are discussed; four action mechanisms are assumed--the effect on insulin secretion and on the sensitivity to it, the effect on the liver, on disturbances of fat metabolism, and on increase of glucose use in the peripheral tissues.

Blood Glucose↗
PubMed1992

Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine.

In a prospective, randomized, assessor-blind multicentre study two antithrombotic subcutaneous regimens were compared in patients undergoing total hip replacement. Group 1 (154 patients) received 750 anti-Xa units of a new low molecular weight heparinoid (Lomoparan) subcutaneously twice a day and group 2 (155 patients) received 5000 units heparin and 0.5 mg dihydroergotamine (heparin-DHE 5000) twice a day. The incidence of deep vein thrombosis, assessed by routine bilateral venography on day 10 (+/- 1), was 17 and 32 per cent in groups 1 and 2 respectively (risk reduction 47 per cent; P = 0.007). One patient in each group developed a symptomatic pulmonary embolism confirmed by lung scanning. Major bleeding complications occurred in one patient in each group and no significant difference was observed between the two groups with respect to minor bleeding complications. Subcutaneous Lomoparan appears to be as safe as heparin-DHE 5000 at the above doses with regard to bleeding complications, and is more efficacious with respect to venous thrombosis.

Aged↗